Loading…
Prestige Consumer Healthcare Inc. is projected to rise to $52.90 by 2027, a +8% move from its current price of $48.90. PBH is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 14 | $47.96 | $48.91 | $49.88 | +0.03% |
| Jul 15 | $47.59 | $48.93 | $50.31 | +0.06% |
| Jul 16 | $47.31 | $48.94 | $50.64 | +0.09% |
| Jul 17 | $47.07 | $48.96 | $50.92 | +0.12% |
| Jul 18 | $46.87 | $48.97 | $51.17 | +0.15% |
| Jul 19 | $46.69 | $48.99 | $51.40 | +0.18% |
| Jul 20 | $46.52 | $49.00 | $51.61 | +0.21% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $46.52 | $49.00 | $51.61 | +0.21% |
| Week 2 | $45.63 | $49.11 | $52.85 | +0.42% |
| Week 3 | $44.98 | $49.21 | $53.84 | +0.63% |
| Week 4 | $44.45 | $49.31 | $54.71 | +0.84% |
| Week 5 | $44.00 | $49.42 | $55.50 | +1.05% |
| Week 6 | $43.61 | $49.52 | $56.23 | +1.27% |
| Week 7 | $43.26 | $49.62 | $56.93 | +1.48% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Prestige Consumer Healthcare Inc. develops, manufactures, markets, distributes, and sells over the counter health and personal care products in North America, Australia, and internationally. It operates in two segments, North American OTC Healthcare and International OTC Healthcare.
The company offers analgesic powders under the BC and Goody's brand; diaper rash treatments and skin protectants for babies under the Boudreaux's Butt Paste brand name; sprays and lozenges to relieve sore throats and mouth pain under the Chloraseptic brand; eye care products that provide relief from redness and itchiness under the Clear Eyes brand name; at-home removal of common and plantar warts under the Compound W brand; and ear wax removal products under the Debrox brand name. It also provides dental guards, floss picks, interdental brushes, dental repair and kits, and tongue cleaners under the DenTek brand; motion sickness relief products under the Dramamine brand; enemas and other laxative products under the Fleet brand name; stomach upset remedies under the Gaviscon brand; cough drops under the Luden's brand; products for yeast infections in women under the Monistat brand name; lice and parasite treatments under the Nix name; feminine care products, including washes, cloths, and sprays under the Summer's Eve brand; products for dry eyes under the TheraTears brand; nasal saline sprays and washes under the Fess brand name; and oral rehydration products under the Hydralyte brand. It sells its products to mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels.
The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.
Prestige Consumer Healthcare Inc. (PBH) is an OTC healthcare company with a diversified portfolio of consumer health brands. It is currently priced at $50.42 and carries a market cap of $2.39B, with a market position that includes a rank of 1924.
A major floor 11.5% below — a decisive break under it would weaken the trend.
The nearest floor, 7.1% below — buyers have tended to step in here.
The nearest ceiling, 3.1% above — a clean break opens room to run.
A major ceiling 41.2% above — clearing it would confirm fresh momentum.
Key PBH support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of PBH market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $48.99 | Sell | $48.79 | Buy |
| MA 10 | $48.72 | Buy | $48.55 | Buy |
| MA 20 | $47.80 | Buy | $48.27 | Buy |
| MA 50 | $48.91 | Sell | $49.90 | Sell |
| MA 100 | $55.37 | Sell | $53.51 | Sell |
| MA 200 | $58.90 | Sell | $58.60 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 51.90 | Neutral |
| Stoch RSI (14) | 70.14 | Neutral |
| CCI (20) | 74.87 | Neutral |
| Williams %R (14) | -30.65 | Info |
| MACD (12,26,9) | 0.30 | Buy |
| ROC (12) | 6.19 | Buy |
| Bollinger %B (20,2) | 0.73 | Neutral |
| Stochastic %K (14) | 69.35 | Neutral |
| TRIX (15) | -0.06 | Sell |
| Awesome (5,34) | 1.35 | Buy |
| Ultimate (7,14,28) | 58.86 | Neutral |
| Momentum (10) | 1.72 | Buy |
| Aroon Osc (25) | 84.00 | Buy |
| Hull MA (9) | 48.94 | Sell |
| ADX (14) | 12.72 | Neutral |
| ATR (14) | 0.98 | Info |
The near-term technical picture is described as bullish in sentiment. The RSI(14) is 60, hovering in a neutral-to-bullish zone.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $45.44 | $48.90 | $63.11 | 0% | Neutral | |
| $43.21 | $52.90 | $67.78 | +8% | Neutral | |
| $43.32 | $54.07 | $71.22 | +11% | Neutral | |
| $46.84 | $59.41 | $79.98 | +21% | Bullish | |
| $48.95 | $62.96 | $86.35 | +29% | Bullish | |
| $55.05 | $71.71 | $99.95 | +47% | Bullish | |
| $62.94 | $82.96 | $117.33 | +70% | Bullish | |
| $64.02 | $85.32 | $122.29 | +74% | Bullish | |
| $67.90 | $91.43 | $132.67 | +87% | Bullish | |
| $69.25 | $94.18 | $138.23 | +93% | Bullish | |
| $99.36 | $141.22 | $217.54 | +189% | Bullish | |
| $152.59 | $233.46 | $386.29 | +377% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $45.44 | $48.90 | $58.84 | +0.00% |
| August 2026 | $43.30 | $50.72 | $60.72 | +3.72% |
| September 2026 | $42.69 | $50.25 | $60.66 | -0.91% |
| October 2026 | $42.65 | $50.42 | $61.28 | +0.34% |
| November 2026 | $43.50 | $51.62 | $63.09 | +2.36% |
| December 2026 | $43.14 | $51.36 | $63.11 | -0.49% |
Click any year to see its month-by-month PBH forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, PBH could reach as high as $63.11, with a base case around $48.90 and support toward $45.44 — roughly 0% from $48.90. A consolidation phase looks the most probable path here.
Expect PBH to range from $43.21 to $67.78 through 2027. The $52.90 average target implies a +8% move from current prices. That is up +8% on the projected 2026 average. Price action looks broadly range-bound.
The PBH price prediction for 2028 points to an average of $54.07 (low $43.32, high $71.22) — a potential gain of +11% on today's $48.90. A consolidation phase looks the most probable path here.
In 2029, PBH is projected to trade between $46.84 and $79.98, averaging $59.41 — a potential gain of +21% from today's $48.90. That is up +10% on the projected 2028 average. Momentum favours further upside here.
Prestige Consumer Healthcare Inc.'s 2030 outlook centres on $62.96, within a $48.95 to $86.35 range. That is up +6% on the projected 2029 average. That marks a +29% change versus current levels. Buyers look set to stay in control over this stretch.
By 2031, PBH could reach as high as $99.95, with a base case around $71.71 and support toward $55.05 — roughly +47% from $48.90. Momentum favours further upside here.
Expect PBH to range from $62.94 to $117.33 through 2032. The $82.96 average target implies a +70% move from current prices. That is up +16% on the projected 2031 average. Buyers look set to stay in control over this stretch.
The PBH price prediction for 2033 points to an average of $85.32 (low $64.02, high $122.29) — a potential gain of +74% on today's $48.90. Momentum favours further upside here.
In 2034, PBH is projected to trade between $67.90 and $132.67, averaging $91.43 — a potential gain of +87% from today's $48.90. That is up +7% on the projected 2033 average. Buyers look set to stay in control over this stretch.
Prestige Consumer Healthcare Inc.'s 2035 outlook centres on $94.18, within a $69.25 to $138.23 range. That is up +3% on the projected 2034 average. That marks a +93% change versus current levels. Momentum favours further upside here.
By 2040, PBH could reach as high as $217.54, with a base case around $141.22 and support toward $99.36 — roughly +189% from $48.90. Buyers look set to stay in control over this stretch.
Expect PBH to range from $152.59 to $386.29 through 2050. The $233.46 average target implies a +377% move from current prices. That is up +65% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in PBH today (≈ 20.449898 PBH) could be worth
$4,774.22
+$3,774.22 (+377%) by 2050 · US Dollar
Based on the average projected PBH price of $233.46 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in PBHwould be worth at today's price.
$1,000 invested in PBH on Jul 10, 2025 (≈ 12.896569 PBH) would be worth
$630.64
-$369.36 (-36.9%) today · 0.63× · US Dollar
Based on a PBH entry price of $77.54 vs. today's $48.9.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $49.42 | $989.48 | -1.1% |
| 1 month ago | $49.13 | $995.32 | -0.5% |
| 3 months ago | $56.55 | $864.72 | -13.5% |
| 6 months ago | $65.3 | $748.85 | -25.1% |
| 1 year ago | $77.54 | $630.64 | -36.9% |
| All time (5.0y) ago | $51.86 | $942.92 | -5.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our PBH forecast.
Our base-case forecast reaches $98.00 around 2040.
Implied market cap at $98.00: $4.64B
The multi-year forecast shows notable upside. The 2030 average price is $65.91 with a ROI of 30.7% and a bullish sentiment; the 2040 average is $149.54 with a ROI of 196.6% and a bullish sentiment; the 2050 average is $246.43 with a ROI of 388.8% and a bullish sentiment. Earlier years show rising estimates, with 2027 avg $54.78, 2028 avg $56.34, and 2029 avg $61.71.
These figures illustrate a generally upward path, indicating substantial longer-term upside, but they are estimates and not guarantees.
Tap a question to reveal the answer.
Average price $65.91; maximum $90.29; minimum $51.30; ROI 30.7%; sentiment BULLISH.
Yes, the forecast shows a rising path with 2026 avg $50.42 and 2030 avg $65.91 (ROI 30.7%), plus 2040 avg $149.54 (ROI 196.6%) and 2050 avg $246.43 (ROI 388.8%), with bullish sentiment in the longer term.
Yes. The 2031 max is $104.83, and the year-by-year path includes higher averages such as 2032 $86.77, 2033 $89.70, 2034 $96.11, and 2035 $98.66, indicating potential to exceed $100 in the near-to-mid term.
Current price: $50.42; Market cap: $2.39B.
Annualized volatility is 40%.
Prestige Consumer Healthcare Inc. Community Discussion
0Share your Prestige Consumer Healthcare Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.